P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

Similar Items

• Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
  by: Chen R, et al.
  Published: (2015-03-01)
• TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
  by: E. A. Demina
  Published: (2017-11-01)
• Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
  by: E A Demina
  Published: (2016-06-01)
• Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
  by: Siddiqi T, et al.
  Published: (2014-02-01)
• COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
  by: G. R. Khachatryan, et al.
  Published: (2016-04-01)